Unit Dose Eye Composition for Oxidative Stress Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diabetic eye diseases, such as diabetic retinopathy and age-related cataracts, are leading causes of blindness due to oxidative stress, inflammation, and mitochondrial dysfunction, with current treatments lacking effective prevention or reduction methods.
Innovation Solution
Unit dose compositions comprising N-acetyl carnosine, S-acetyl glutathione, pterostilbene, N-acetyl cysteine, lutein, taurine, thiamine, lycopene, and zeaxanthin, or their pharmaceutically acceptable salts, administered to improve eye function and treat or prevent eye diseases by reducing inflammation and oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for diabetic eye disease, then current standard care is provided, but effective prevention or reduction of oxidative stress and inflammation is not achieved
Solution Approach 1:
The patent combines multiple antioxidants and anti-inflammatory compounds (vitamin C, vitamin E, astaxanthin, lutein, zeaxanthin, taurine, N-acetyl carnitine, acetyl-L-carnitine) into a composite pharmaceutical composition. This composite approach synergistically addresses oxidative stress and inflammation through multiple mechanisms simultaneously, providing more effective prevention and treatment of diabetic eye disease compared to single-agent therapies.
2Reliability
If a combination of multiple antioxidants and anti-inflammatory compounds is administered, then eye function is improved and oxidative stress is reduced, but the complexity of the composition increases
Solution Approach 1:
The patent merges multiple beneficial compounds into a single integrated pharmaceutical composition that can be administered together. This combining approach delivers multiple therapeutic effects (antioxidant protection, anti-inflammatory action, mitochondrial support) simultaneously through one formulation, improving eye function while managing complexity through unified delivery rather than multiple separate treatments.
Solution Approach 2:
The pharmaceutical composition is designed with multi-functionality, where the same combination of compounds addresses multiple pathological mechanisms of diabetic eye disease including oxidative stress, inflammation, and mitochondrial dysfunction. This universal approach allows one composition to perform multiple therapeutic functions, reducing the need for multiple separate interventions.
3Object-affected harmful factors
If antioxidants are administered to reduce oxidative stress, then mitochondrial DNA damage is prevented, but the ability to address multiple disease mechanisms simultaneously is limited
Solution Approach 1:
The patent employs a composite formulation containing antioxidants (vitamin C, vitamin E, astaxanthin, lutein, zeaxanthin), anti-inflammatory agents (taurine, N-acetyl carnitine, acetyl-L-carnitine), and other supportive compounds. This composite material simultaneously protects against mitochondrial DNA damage through antioxidant mechanisms while also addressing inflammation, improving blood flow, and supporting overall retinal health, thereby achieving versatility across multiple disease mechanisms.
Data Source
AI summary
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to unit dose compositions comprising (a) N-acetyl carnosine or a pharmaceutically acceptable salt thereof; (b) S-acetyl glutathione or a pharmaceutically acceptable salt thereof; (c) pterostilbene or a pharmaceutically acceptable salt thereof; (d) N-acetyl cysteine or a pharmaceutically acceptable salt thereof; (e) lutein or a pharmaceutically acceptable salt thereof; (f) taurine or a pharmaceutically acceptable salt thereof; (g) thiamine or a pharmaceutically acceptable salt thereof; (h) lycopene or a pharmaceutically acceptable salt thereof; and (i) zeaxanthin or a pharmaceutically acceptable salt thereof. In one aspect, the unit dose compositions improve eye function in a subject. In another aspect, the unit dose compositions treat or prevent eye disease is a subject.